Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786343 · ClinicalTrials.gov registry record · Phase 2
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT01786343: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01786343 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01786343, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML. Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2013-02-05 |
| Est. Completion | 2019-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786343
The ClinicalTrials.gov registry entry for NCT01786343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT01786343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786343 about?
NCT01786343 is a clinical study titled "Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)". The goal of this clinical research study is to compare how well 2 different dosing schedules of decitabine may help control AML. Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to die.
What is the current status of trial NCT01786343?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2013-02-05. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT01786343?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT01786343?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.